Vanguard Health Care Fund is the over-5% client exception in Celldex Therapeutics (CLDX) stake amendment.
Wellington Management Group LLP and its affiliated entities have filed an amended Schedule 13G for Celldex Therapeutics (CLDX), reporting beneficial ownership of 10,951,399 common shares, representing 13.95% of the class. The filing identifies Vanguard Health Care Fund as an exception to the statement that no single client holds more than 5% of the shares. This disclosure details the voting and dispositive powers held by the various Wellington entities.
Celldex Stock In Focus After Earnings Loss And Shelf Filing
Celldex Therapeutics reported a significant net loss of US$75.56 million in Q3 2026, alongside a new universal shelf registration for future equity offerings. This move underscores the company's need for external capital to fund its antibody pipeline, particularly the barzolvolimab program, given its minimal current revenue. The market's focus remains on potential dilution risks and the company's ability to finance its clinical development through to product launch.
Form S-3ASR Celldex Therapeutics Inc For: 6 November By Investing.com
This article announces that Celldex Therapeutics Inc. filed a Form S-3ASR on November 6. The filing is a significant regulatory action that could relate to future stock offerings or other corporate actions, impacting the company's stock performance. The article also notes the company's stock symbol CLDX and its current performance.
A chronic-hives drug met every key goal in two trials. Celldex expects to file for approval in 2027.
Celldex reported positive results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies for barzolvolimab in chronic spontaneous urticaria (CSU), meeting all primary and key secondary endpoints. The company plans to file a biologics license application (BLA) for barzolvolimab in 2027 and expects its current funding to support planned operations through 2028. Additionally, Celldex provided a corporate update, including financial results for the third quarter of 2026 and progress on other pipeline programs.
Celldex Therapeutics earnings beat by $0.06, revenue fell short of estimates
Celldex Therapeutics (NASDAQ: CLDX) reported third-quarter EPS of $-0.96, surpassing analyst estimates by $0.06. However, the company's revenue of $400K fell short of the consensus estimate of $725.75K. The stock has seen a 32.22% decrease in the last three months but is up 23.45% over the past 12 months.
Celldex Reports Third Quarter Financial Results and Provides Corporate Update
Celldex reported its third-quarter 2026 financial results and provided a corporate update, highlighting positive Phase 3 study results for barzolvolimab in Chronic Spontaneous Urticaria (CSU), with a Biologics License Application (BLA) anticipated in 2027. The company is also advancing other pipeline programs, including a Phase 3 study for barzolvolimab in cold urticaria and symptomatic dermographism, and a Phase 1 study for CDX-622 in asthma. Financially, Celldex reported a net loss of $75.6 million for the quarter but believes its cash position is sufficient to fund operations through 2028.
CLDX: Celldex Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas
This article provides an overview of Celldex Therapeutics Inc. (CLDX), including its current stock price, market capitalization, fundamentals, and recent news. It highlights the company's focus on developing novel therapeutics for cancer and other diseases, lists its drug candidates, and mentions a recent analyst price target increase. The article also includes a sentiment poll and links to related news and discussions.
Celldex will give two conference talks; replays will be available for 90 days.
Celldex (NASDAQ:CLDX) announced that its management will participate in fireside chats at two upcoming healthcare investor conferences in November and December 2026. The Guggenheim 3rd Annual Healthcare Innovation Conference chat is scheduled for November 9, 2026, and the 9th Annual Evercore Healthcare Conference chat is on December 1, 2026. Webcasts of these presentations will be available on Celldex’s investor website, with replays accessible for 90 days following each event.
Celldex to Present at Upcoming Investor Conferences
Celldex (NASDAQ:CLDX) announced its management will participate in fireside chats at two upcoming investor conferences: the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026, and the 9th Annual Evercore Healthcare Conference on December 1, 2026. Webcasts of these presentations will be available on the "Events and Presentations" page of the "Investors" section of the Celldex Website, with replays accessible for 90 days. Celldex is focused on developing novel antibody-based treatments for allergic, inflammatory, and autoimmune disorders.
Celldex Therapeutics, Inc. (CLDX) Seasonal returns chart
This article provides a seasonality chart for Celldex Therapeutics, Inc. (CLDX), showing the average monthly price return from 2016 to 2026. The stock's current real-time price on NasdaqCM is also displayed. This data can be used by investors to analyze potential seasonal trends in the company's stock performance.
Celldex Therapeutics, Inc. Estimates – NASDAQ:CLDX
This article provides an overview of Celldex Therapeutics, Inc. (NASDAQ: CLDX) financial data and analyst estimates available on TradingView. It highlights sections for income statements, balance sheets, cash flow, and valuation metrics, allowing users to compare actual results with various estimates and track trends over time. The content primarily serves as a guide to financial data and disclaims investment advice.
Celldex Therapeutics, Inc. Estimates – LSX:A2PEAB
This article provides an overview of Celldex Therapeutics, Inc. (A2PEAB) financial estimates and actuals, accessible through TradingView. It allows users to explore reported financial data and analyst estimates for the income statement, balance sheet, cash flow statement, and various valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time.
HC Wainwright sets USD 64.00 target for Celldex Therapeutics stock
HC Wainwright has reiterated a Buy rating and set a USD 64.00 price target for Celldex Therapeutics, indicating a significant upside from its current trading price. This valuation largely depends on future clinical execution rather than recent financial performance, as the company reported a second-quarter revenue of USD 0.02 million and an earnings per share of minus USD 0.94. Investors are now looking to the next earnings report on November 9, 2026, for updates on clinical progress and development timelines.
Celldex Therapeutics stock fell 4.84 percent to USD 27.53 on October 16, 2026
Celldex Therapeutics (CLDX) stock declined by 4.84% to USD 27.53 on October 16, 2026, closing significantly below its 52-week high but above its 52-week low. The company, which develops antibody-based therapies, is estimated to report its third-quarter results on November 9, 2026, with analysts projecting a loss per share and low revenue. Despite the dip, the stock's closing price was still up 1.50% from its start-of-year level, and analysts maintain a much higher average target price of USD 61.92.
November 9 earnings date set for Celldex Therapeutics stock
Celldex Therapeutics (CLDX) has set November 9, 2026, as its next estimated earnings date, providing investors with an upcoming milestone for the clinical-stage biotechnology company. As of October 15, 2026, the company held a market capitalization of USD 2.3 billion, with its stock trading at EUR 25.46 on Lang & Schwarz and USD 28.67 on Nasdaq. Celldex, which focuses on antibody-based treatments for inflammatory diseases and cancer, currently has a negative P/E ratio of -6.55 and does not pay a dividend.
Law firm investigates Celldex Therapeutics for possible breach of fiduciary duties.
Purcell & Lefkowitz LLP is investigating Celldex Therapeutics to determine if the company's directors breached their fiduciary duties through recent corporate actions. This investigation, highlighted by Pluang's health sector data, could impact shareholder confidence and the company's governance. The article notes recent movements in health stocks, with CTXR, XRAY, and DNA showing slight declines.
Celldex Therapeutics Inc (TCE2.MU) Analyst insights, Price targets and Recommendations
The article provides a snapshot of recent analyst ratings and recommendations for Celldex Therapeutics Inc (TCE2.MU), detailing upgrades, downgrades, and maintained ratings from various financial institutions. It shows that analysts from HC Wainwright & Co., Leerink Partners, Morgan Stanley, and Cantor Fitzgerald have reiterated positive stances on the stock, mostly maintaining Buy or Overweight ratings. The stock price was 27.12 EUR, down 1.67% as of the market opening.
FMR LLC and Abigail P. Johnson Reveal 10.7% Stake in Celldex Therapeutics Inc.
FMR LLC and Abigail P. Johnson have disclosed a 10.7% beneficial ownership stake in Celldex Therapeutics Inc. as of September 30, 2026. This information was detailed in an Amendment No. 7 to their Schedule 13G filing with the SEC on October 6, 2026. Both entities reported owning 8,411,905.03 shares of Celldex Therapeutics common stock.
An investment firm reports a passive stake of 8.4 million shares in Celldex Therapeutics (CLDX).
FMR LLC has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Celldex Therapeutics (CLDX), reporting beneficial ownership of 8,411,905 shares, which represents a 10.7% stake in the company. The filing indicates that FMR LLC holds sole voting power over 8,396,651 shares and sole dispositive power over 8,411,905 shares. Abigail P. Johnson is also listed with sole dispositive power over the same number of shares but no sole voting power.
Celldex reports Phase 3 success as HC Wainwright rates Celldex Therapeutics stock Buy
Celldex Therapeutics reported positive Phase 3 results for barzolvolimab, with significant complete response rates in both primary and omalizumab-refractory subgroups. HC Wainwright reaffirmed a Buy rating and a $64.00 price target, highlighting the drug's clinical success. However, Goldman Sachs maintains a Hold rating with a $28.00 target, showing a wide disparity in analyst expectations due to ongoing development costs and future regulatory hurdles.
Celldex reports Phase 3 success as HC Wainwright rates Celldex Therapeutics stock Buy
Celldex Therapeutics reported positive Phase 3 results for barzolvolimab, with significant complete response rates in chronic spontaneous urticaria studies. HC Wainwright reaffirmed a Buy rating with a $64.00 price objective, while Goldman Sachs maintained a Hold rating and a $28.00 target, highlighting a wide valuation gap. The company plans to submit a Biologics License Application in 2027 despite incurring substantial net losses in Q2 2026 due to its pipeline strategy.
Celldex Therapeutics Inc (TCE2.MU) Analyst insights, Price targets and Recommendations
This article provides an overview of recent analyst ratings for Celldex Therapeutics Inc (TCE2.MU), noting several firms reiterating "Buy," "Outperform," and "Overweight" ratings throughout September and October 2026. The stock was trading at 27.58 EUR, down 5.26%. The content focuses primarily on analyst upgrades and downgrades for the company.
Celldex Therapeutics stock reports strong Phase 3 trial results
Celldex Therapeutics announced positive results from two Phase 3 studies (EMBARQ-CSU1 and EMBARQ-CSU2) for its drug barzolvolimab, which met primary and key secondary endpoints in treating chronic spontaneous urticaria. Complete response rates reached up to 54.0 percent in treated groups compared to placebo. Analysts maintain a "Moderate Buy" consensus with price targets significantly above the current stock price, despite ongoing trials and regulatory hurdles.
Weekly Recap: Physicians favor barzolvolimab and $64–$88 analyst range
Physician sentiment regarding Celldex Therapeutics' (NASDAQ: CLDX) barzolvolimab is largely positive, with most doctors expressing willingness to prescribe the drug despite safety concerns. Meanwhile, recent analyst price targets for Celldex Therapeutics show a significant valuation spread, ranging from $64 to $88, reflecting differing outlooks on the company's future. This recap highlights both clinical reception and financial projections for CLDX.
Celldex announces Phase 3 barzolvolimab trials meet primary and all key secondary endpoints
Celldex Therapeutics reported positive results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials for barzolvolimab, which met both primary and all key secondary endpoints. The drug demonstrated rapid, profound, and sustained efficacy with a favorable safety profile. Celldex plans to submit a Biologics License Application (BLA) to the FDA in 2027.
Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About?
Celldex Therapeutics, Inc. (CLDX) is drawing market attention after its barzolvolimab studies in chronic spontaneous urticaria met primary and key secondary endpoints. This development highlights the company's operating priorities and its position within the Healthcare Stocks sector. Investors are now focused on consistent execution and how these positive clinical results translate into sustained operational success and customer response.
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64
H.C. Wainwright has reiterated its Buy rating for Celldex Therapeutics (CLDX.US), maintaining a target price of $64. This indicates continued confidence from the analyst firm in the company's prospects.
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
Celldex Therapeutics (CLDX) recently announced positive Phase 3 trial results for its lead asset, barzolvolimab, in chronic spontaneous urticaria, demonstrating best-in-disease efficacy and high rates of complete response. While the company has a strong cash balance and a broad pipeline, it faces a heavy burn rate with widening net losses and a BLA submission not expected until 2027. The market is divided on CLDX, reflecting both the clinical promise of barzolvolimab and the financial challenges and mixed results from other programs.
Celldex Therapeutics upgraded to Buy after positive Phase 3 trial results for skin drug barzolvolimab.
Celldex Therapeutics received a "Buy" rating upgrade from H.C. Wainwright, with a price target increase to $64 from $42, following successful Phase 3 trials for its skin drug barzolvolimab. The drug demonstrated rapid and lasting benefits for patients with a chronic skin condition, and Celldex plans to seek FDA approval in 2027. This development highlights significant progress for the company and provides context for the positive performance of health-sector stocks.
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
This article highlights four biotechnology stocks—Kodiak Sciences (KOD), Celldex Therapeutics (CLDX), Rapport Therapeutics (RAPP), and Vaxcyte (PCVX)—that are anticipating crucial mid- to late-stage clinical trial readouts this fall. These readouts are significant catalysts that can dramatically impact investor perceptions of a drug's efficacy, safety, and commercial potential, leading to substantial stock price movements. The outcomes of these trials, spanning ophthalmology, immunology, neuroscience, and vaccines, are expected to influence the future development and market prospects of each company’s pipeline.
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
Celldex Therapeutics announced positive top-line results from its Phase III EMBARQ-CSU trials for barzolvolimab, a treatment for chronic spontaneous urticaria (CSU). Both dosing regimens met primary and key secondary endpoints, showing significant and durable improvements in UAS7 scores and high rates of complete response, including in omalizumab-refractory patients and those with angioedema. The safety profile was consistent with previous studies, and Celldex plans to submit a Biologics License Application (BLA) in 2027.
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex Therapeutics announced positive topline results from its Phase 3 EMBARQ-CSU clinical trials for barzolvolimab, a treatment for chronic spontaneous urticaria (CSU). Both trials met primary and key secondary endpoints, showing significant improvement in patients, including those refractory to existing therapies. The company plans to submit a Biologics License Application (BLA) to the FDA in 2027 based on these favorable results and a consistent safety profile.
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
This article highlights four biotech companies—Kodiak Sciences (KOD), Celldex Therapeutics (CLDX), Rapport Therapeutics (RAPP), and Vaxcyte (PCVX)—that have significant clinical readouts anticipated this fall. These readouts are critical catalysts for biotech stocks, as positive or negative data can substantially impact investor expectations and stock valuations. The companies are advancing drug candidates in ophthalmology, immunology, neuroscience, and vaccines, with potential for major valuation shifts based on study outcomes.
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials
Celldex Therapeutics announced that its drug Barzolvolimab met the primary and all key secondary endpoints in two Phase 3 trials for chronic spontaneous urticaria. This positive outcome follows a recent setback where the company discontinued a Phase 2 study for the same drug in Prurigo Nodularis due to missing its primary endpoint. Despite the mixed results, analysts maintain an "Overweight" rating on Celldex, with an average target price significantly above the current stock price.
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials
Celldex Therapeutics saw its shares rise 8% after announcing positive topline results from two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) for its drug barzolvolimab in patients with chronic spontaneous urticaria (CSU). Both trials met primary and key secondary endpoints, showing significant improvements in disease activity and complete response rates compared to placebo, even in difficult-to-treat patients. Celldex plans to submit a Biologics License Application (BLA) for barzolvolimab to the FDA in 2027.
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials
Celldex Therapeutics announced that its drug barzolvolimab met primary endpoints in two Phase 3 trials for chronic spontaneous urticaria. The article, however, is a premium content piece from MT Newswires, requiring a subscription to Yahoo Finance Gold or Silver to access the full details.
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Celldex (NASDAQ:CLDX) reported positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials for barzolvolimab in patients with chronic spontaneous urticaria (CSU), meeting primary and all key secondary endpoints. The studies demonstrated rapid, profound, and sustained efficacy, with a favorable safety profile. Celldex plans to submit a Biologics License Application (BLA) in 2027, positioning barzolvolimab as a potential transformational therapy for CSU, including those refractory to existing treatments.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
Purcell & Lefkowitz LLP has launched a shareholder investigation into Celldex Therapeutics, Inc. (NASDAQ: CLDX) to determine if the company's directors breached their fiduciary duties through recent corporate actions. Shareholders of Celldex Therapeutics are encouraged to contact the firm for more information regarding their rights and options. Purcell & Lefkowitz LLP specializes in representing shareholders affected by securities fraud and corporate misconduct.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of "Moderate Buy" by Brokerages
Celldex Therapeutics (NASDAQ:CLDX) has received a consensus "Moderate Buy" rating from thirteen research firms, with an average 12-month price target of $56.42. The company recently reported quarterly EPS of -$0.94, surpassing estimates, though revenue fell short. Several institutional investors have significantly increased their holdings in CLDX, and analysts expect a full-year loss of approximately $4.17 per share.
Celldex to Present at Upcoming Investor Conference
Celldex Therapeutics, Inc. announced that its management will participate in a fireside chat at the Cantor Global Healthcare Conference on September 10, 2026, at 8:00 AM ET. A webcast of the presentation will be available on the "Events and Presentations" page of the "Investors" section of the Celldex Website, with replays available for 90 days. Celldex focuses on pioneering antibody-based treatments for allergic, inflammatory, and autoimmune disorders.
Celldex to Present at Upcoming Investor Conference
Celldex announced that its management will participate in a fireside chat at the Cantor Global Healthcare Conference on September 10, 2026, at 8:00 AM ET. A webcast of the presentation will be available on the "Events and Presentations" page of the "Investors" section of the Celldex Website, with replays available for 90 days. The company focuses on pioneering new horizons in immunology to deliver life-changing therapies for allergic, inflammatory, and autoimmune disorders.
Discipline and Rules-Based Execution in CLDX Response
The article analyzes Celldex Therapeutics Inc. (NASDAQ: CLDX), noting weak near and mid-term sentiment despite a strong long-term outlook. It highlights a significant 42.0:1 risk-reward setup targeting a 12.4% gain against 0.3% risk, and provides three AI-generated trading strategies for different risk profiles. The analysis emphasizes rules-based execution and sophisticated risk management.
Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX
Celldex Therapeutics, Inc. (NASDAQ:CLDX) generated $1.54 million USD in revenue last year, primarily from its "Novel Therapeutics for Human Health Care" segment. This figure represents a decrease from the $7.02 million USD reported the previous year. The United States was the largest contributor to the company's revenue, mirroring the overall revenue figures.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $56.08, exceeding its current share price of $41.70. While recent analyst actions were mixed, including Guggenheim raising its target to $100 and Cantor Fitzgerald cutting its target to $61, the overall sentiment remains positive. The company reported a quarterly loss of $0.94 per share, beating expectations, but revenue of $0.02 million missed estimates significantly.
Celldex Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
Celldex Therapeutics (NASDAQ: CLDX) has approximately 203 employees worldwide as of March 2026, representing a 26.1% growth since 2023. The company is actively hiring, with 27 job postings in 2026, a 70% increase from 2025. Its workforce is primarily concentrated in North America, with an average salary of $153,662.
Celldex Therapeutics, Inc. $CLDX Shares Acquired by Bank of America Corp DE
Bank of America Corp DE significantly increased its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 70.8% in the first quarter, now owning 708,647 shares valued at $22.5 million. This comes as Celldex, a clinical-stage biopharmaceutical company, reported a smaller-than-expected quarterly loss of $0.94 per share. Analysts maintain a "Moderate Buy" consensus rating for CLDX, with an average price target of $55.46.
Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake
Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 6.78% in Celldex Therapeutics, Inc. This ownership translates to shared voting and dispositive power over 5,322,908 shares of Celldex's common stock. The filing, a SCHEDULE 13G/A, indicates that no single entity among the reporting persons holds sole voting or dispositive power over these shares.
T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G
T. Rowe Price Associates has disclosed a 6.0% beneficial ownership stake in Celldex Therapeutics Inc. (CLDX) through a Schedule 13G filing. The firm reported holding 4,686,187 shares of common stock, with sole voting power over 4,683,226 shares and sole dispositive power over all 4,686,187 shares. Despite the disclosure, T. Rowe Price Associates explicitly states that this report should not be interpreted as an admission of beneficial ownership.
Celldex Therapeutics (CLDX) Reported Wider Losses, Is It Still Undervalued?
Celldex Therapeutics (CLDX) recently reported wider losses and lower revenue for Q2 and H1 2026, yet its stock has seen significant recent gains. While the company trades at a 4.9x Price-to-Book multiple, suggesting it's overvalued compared to peers, a Discounted Cash Flow (DCF) model indicates it's trading 61.1% below its estimated intrinsic value of $113.93 per share. Investors are left to weigh the company's widening losses and P/B valuation against its strong recent stock performance and potential future cash flow value.
Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX
Sei Investments Co. recently acquired a new stake of 38,152 shares in Celldex Therapeutics, Inc., valued at approximately $1.21 million. This comes as several other hedge funds have also adjusted their positions in the biopharmaceutical company. Celldex Therapeutics reported better-than-expected quarterly earnings and has received new price targets from analysts, with a consensus of "Moderate Buy."